Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.57 | N/A | +13.28% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.57 | N/A | +13.28% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook, emphasizing their commitment to long-term objectives. They acknowledged the challenges faced in the current quarter.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on its long-term strategic goals despite the current financial performance.
Nektar Therapeutics reported a wider-than-expected loss per share, which surprised investors positively, but the lack of revenue data and guidance contributed to a slight decline in stock price. The stock fell by 1.19% as investors reacted to the overall uncertainty surrounding future performance. Management's defensive tone may indicate challenges ahead, but they remain focused on long-term goals.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
INSULET CORP
Feb 25, 2019